相关实验视频

Updated: May 13, 2026

Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay EMSA and DNA-affinity Precipitation Assay DAPA
11:35

Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay EMSA and DNA-affinity Precipitation Assay DAPA

Published on: August 21, 2016

13.1K

PNPLA3 I148M变体与MASLD中的免疫细胞透和晚期纤维化有关:一个前性基因型-表型研究

Jaejun Lee1,2, Jung Hoon Cha2, Hee Sun Cho1,2

  • 1Division of Hepatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.

Journal of gastroenterology
|July 21, 2025
PubMed
概括

PNPLA3 I148M变体与代谢功能障碍相关的脂肪性肝病 (MASLD) 中免疫细胞透和激活的增加有关. 这一遗传因素与MASLD患者的肝炎和纤维化进展有关.

关键词:
免疫细胞是免疫细胞.肝脏纤维化 肝脏纤维化与代谢功能障碍相关的脂肪性肝病.这是一种PNPLA3蛋白.

更多相关视频

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues07:17

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues

Published on: August 23, 2024

1.3K
Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma10:21

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

544

相关概念视频

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...